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8.1  Introduction 
There is a growing concern in the United  States about shortfalls in 
health care quality. One influential Institute of  Medicine (IOM) study 
called attention to problems of underuse, overuse, and misuse in health 
care quality (IOM 2000). With regard to underuse, there are a wide variety 
of procedures that are proven to be effective, yet are often used at rates as 
low as 50 percent for appropriate patients (most recently, see McGlynn et 
al. 2003). Examples of such effective treatments include the use of beta- 
blockers and aspirin for appropriate heart attack patients, annual eye ex- 
aminations for people with diabetes, and mammography examinations for 
women over age fifty. 
By the same token, there is evidence of overuse of procedures where they 
are not appropriate. For example, 20 percent of antibiotics prescribed in 
1992  were used for common colds and respiratory tract infections, illnesses 
where the effectiveness  of such antibiotics is questionable and may even be 
harmful. By the same token, only about one-third of angioplasties (PTCA) 
for cardiovascular disease are clearly appropriate, with about one-half 
uncertain and the remainder inappropriate (Schneider et al. 2001). Tech- 
nological advances in diagnostic methods to detect appendicitis such as 
computerized tomography have improved tremendously, but there has been 
no apparent decline in the rate of  inappropriate surgery for appendicitis 
(Flum et al. 2001). Finally, there is some evidence on the misuse of care, 
whether that means resulting complications resulting from errors in the 
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treatment of a disease or (more generally) whether it means a poor match 
between what the patient wants (in terms of risk and side effects) and what 
the patient actually receives (Wennberg, Fisher, and Skinner 2002).’ 
This paper focuses on the underuse of effective procedures and, in par- 
ticular, the remarkable variation across regions in the United States with 
regard to the use of such treatments. Geographical variation in quality of 
care is of interest for two reasons. First, it provides a snapshot of the degree 
of technological inefficiency in the health care system; that is, how much 
do some regions and hospitals lag behind best-practice practiced in other 
areas? It is not surprising that health care innovations take time to dif- 
fuse; physicians need to be trained in the use of new technology (perhaps 
through residency programs), and their use spreads as the newly trained 
residents diffuse to new practice areas. What is more surprising is how per- 
sistent are the shortfalls in quality across regions. 
For example, beta-blockers are used to reduce demands on weakened 
hearts following acute myocardial infarction (AMI), with well-established 
benefits in terms of reduced mortality. As Jencks, Huff, and Cuerdon 
(2003) reported, median state level of use among ideal patients is just 69 
percent in 2000 and 2001. Yet beta-blockers have been known to be effec- 
tive for many years; in 1985, Yusuf et al. concluded that “Long-term beta 
blockade for perhaps a year or so following discharge after an MI is now 
of proven value, and for many such patients mortality reductions of about 
25% can be achieved” (335). In other words, despite the passage of nearly 
two decades since beta-blockers had become well established and inexpen- 
sive treatment for heart attacks, roughly 30 percent of AM1 patients are 
still not getting appropriate treatment.2 Similarly, Garg et al. (2002) have 
found an average of 42 percent of heart attack patients for whom angiog- 
raphy was deemed “necessary” actually received the angiography, with re- 
gional rates varying from 24 to 58 percent. 
To  quantify  the  degree of  technological  process  inefficiency in  the 
United  States, I use  data from the  Dartmouth  Cardiovascular Atlas of 
Health Cure (Wennberg and Birkmeyer 2000) that, in turn, is based on a 
large detailed survey (with chart reviews) of more than 160,000 heart at- 
tack patients during 1994 and 1995. I find that the average loss per heart 
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attack patient, relative to best-practice care, is between $1,500 and $5,000 
per year, depending on the benchmark used, the value of a life year, and 
other assumptions. The measured inefficiency does not stem from specific 
skills of  the surgeon, but instead largely reflects the use (or nonuse) of 
pharmaceuticals such as beta-blockers and aspirin. 
Geographic variation is used for a second task, to estimate a reduced 
form model of technology adoption that depends on supply factors that 
might be expected to lower the cost of adapting the new technology, such 
as the prevalence of cardiologists-who  are presumably most aware of new 
technologies in the use of health care innovations-and  demand factors 
such as education, income, and the overall incidence of heart disease in the 
region. Supply factors are less important in explaining technology diffu- 
sion than expected, but estimated demand effects are significant both sta- 
tistically and economically. More cardiologists per capita is not signifi- 
cantly associated with higher rates of  beta-blocker use, nor is there an 
association between cardiologists supply and the uveruge quality use rate 
for beta-blockers, aspirin, reperfusion, and angiotensin converting enzyme 
(ACE) inhibitors. 
In conclusion, there seems to be a missing link between the potentially 
large benefits of effective care for heart attack patients and financial in- 
centives to pay for them. While beta-blockers may not be reimbursed di- 
rectly by  the Medicare program (and indeed cost just pennies per dose), 
other procedures with uncertain (or potentially negative) effects on out- 
comes, such as nonprimary angioplasty or angioplasty for non-Q-wave 
heart attacks, are paid in full by Medi~are.~  An intriguing question that re- 
mains is why physicians working in hospital settings do not comply with 
quality guidelines, given the large benefits in terms of patient outcome to 
do so. 
8.2  Theoretical Models of Technology Adoption and Quality of Care 
Standard economic models begin with the assumption of profit maxi- 
mization, and it is not surprising that such models predict that firms with 
the greatest expected gain from adopting new technology should be the 
ones to do so (e.g., Griliches 1957). In the context of health care, financial 
incentives are largely determined by the reimbursement policies of insur- 
ance programs, most notably the Medicare program. For most measures of 
effective care, however, the financial costs of  adopting pharmaceutical 
technology is minimal, particularly  for beta-blockers and aspirin where 
costs are measured in cents rather than in dollars. 
The exception is reperfusion therapy for heart attack patients, which 
3. Fisher and Skinner (2001) found a negative correlation between Medicare spending and 
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may consist either of primary angioplasty within twenty-four hours of the 
heart attack, or a regime of thrombolytic drugs, again administered shortly 
after the heart attack. The surgical approach, angioplasty, involves the use 
of a small deflated “balloon” inserted through a vein and threaded up to 
the blockage area, where it is popped open, thus generally restoring blood 
flow to the oxygen-starved heart muscle. The pharmaceutical approach 
uses “clot buster” thrombolytics that help to dissolve the platelets and 
other deposits that contribute to blocking blood flow to the heart; they are 
generally not used together because the thrombolytics discourages clot- 
ting, which can be dangerous during surgery. In this case, Medicare does 
compensate generously for surgery, thus providing a strong profit motive 
for investing in the newer technology. However, because the Medicare sys- 
tem is federal, it generally pays similar amounts across regions (albeit ad- 
justed for costs of living, low-income patients, and graduate medical pro- 
grams). While theoretical models would predict the more rapid diffusion 
of the most profitable (to hospitals or physicians) technologies, they do 
not generally predict why  some regions would become persistently late 
adopters (see Skinner and Staiger 2005). Thus, one cannot appeal to differ- 
ences in reimbursement rates to explain why regions in the UniteddStates 
differ so much with regard to technology adoption, particularly as the 
technologies I consider in the following are not particularly costly (i.e., as- 
pirin or beta-blockers). 
The literature in health care quality improvement is quite different and 
focuses much less on financial incentives and more on organizations and 
personalities. Indeed, the dominant model (adopted in turn from the man- 
agement literature) sorts personalities of the relevant individuals accord- 
ing to whether they are innovators, early adopters, early or late majority 
adopters, and laggards (for an excellent review, see Berwick 2003). Some of 
these differences may, of course, stem from the organizational structure of 
the hospitals or the educational systems whence they emerge. As well, so- 
cial networks (Coleman, Katz, and Menzel 1966) are another important 
mechanism for the transmission of medical innovations. These factors may 
be reflected in peer effects as found by Epstein and Nicholson (2005) and 
Burke, Fournier, and Prasad (2003). 
We therefore consider quite general hypotheses based on a large class of 
factors on both the supply and demand side of health care markets. On the 
supply side, cardiologists might be expected to adopt earliest, as their prac- 
tice is almost exclusively for patients with cardiovascular care, and they 
have received advanced training in cardiac care. As well, physicians would 
have the greatest incentive to adopt efficacious care the greater is the over- 
all burden of cardiovascular disease or when urban dense regions increase 
the potential for specialization. On the other hand, demand-side factors 
could increase pressure on physicians to innovate; one might hypothesize 
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with new treatments and play a more active role in their use. (Conversely, 
they might be less likely to refuse the new treatment.) 
This simple model suggests two distinct empirical exercises. The first is 
to attempt to quantify the gains from adopting more efficient technologies, 
which in the empirical section I define as the use of beta-blockers, ACE in- 
hibitors, aspirin, and reperfusion in the treatment of AMI. Given those 
measures, factors (supply or demand) are next considered that may affect 
the adoption of one of these innovations in particular-both  with regard 
to the use of beta-blockers and with regard to a set of effective treatments 
for AMI. 
8.3  Empirical Measures of Technology Adoption and Quality of Care 
In measuring technological diffusion for the treatment of heart attack 
patients, it is important to note that the technologies considered are not 
particularly hi-tech: beta-blockers and aspirin have been used for many 
years in the treatment of other illnesses, but their use for heart attack pa- 
tients was established conclusively several decades ago (see Yusuf et al. 
[  19851 and Heidenreich and McClellan [2001]). These treatments can be 
viewed as efJicient care that is appropriate for nearly 100 percent of the ap- 
propriate patient population, regardless of health status or nearly any set 
of  preference^.^ Problems with measuring health status, or with the true 
underlying preferences, are therefore greatly reduced, as everyone should 
demand the treatment, and the right rate does not depend on health sta- 
tus-as  it is as close to 100 percent as one can get. 
The disadvantage with measuring quality in this way is that it comprises 
a small fraction of how health care is actually practiced. The vast majority 
of decisions require much greater degrees of judgment, where a treatment 
choice may be appropriate and helpful for one patient but inappropriate 
and even harmful for another. For example, roughly 15 percent of angio- 
plasty (a less invasive approach than bypass surgery to restoring blood flow 
to arteries in the heart) are deemed inappropriate, and about half are of 
uncertain benefit (Schneider et al. 200 1). As well, treatment for chronically 
ill patients with diseases such as congestive heart failure, cancer, or pul- 
monary diseases differ widely across regions in the United States, and as- 
sessing how many physician visits are appropriate, or the appropriate level 
of  intensive care unit (ICU) care, is difficult even with detailed clinical 
data.5 
Some approaches focus on outcomes measures, such as mortality rates 
or complication rates, but such measures must first control for possible 
4. The terminology here follows Wennberg, Fisher, and Skinner (2002). 
5. This type of care, which accounts for nearly all of the variation across regions in the 
United States, is referred to as supply sensitive care because such care tends to be associated 
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differences in the initial health status of the patient population. One ex- 
ample of an output measure of quality is the thirty-day or one-year mor- 
tality rate following AMI. The advantage of this type of measure is that it 
is a summary statistic and thus captures the multidimensional vector of in- 
puts including the quality of the surgical team, follow-up care, smoking 
cessation programs, and the myriad other factors that comprise quality but 
which are difficult, if not impossible, to measure. 
There are several shortcomings with measuring quality in this way, how- 
ever. The first is simply the small numbers problem. If a hospital admits 
thirty AM1 patients, purely random variation in the health status of the pa- 
tient may lead to say six deaths in one year and nine deaths the next year. 
Thus, one cannot clearly determine whether the hospital looks better (or 
worse) than average because the hospital is better (or worse), or because 
the hospital  had several lucky or unlucky draws. While McClellan and 
Staiger (1999) have used filtering methods at the hospital level to address 
this problem, it is still difficult to infer much about quality of care from 
smaller hospitals. 
Another way around this problem is to aggregate individual hospitals 
into larger regions. This latter method was used in the Dartmouth Atlas of 
Health Cure (Wennberg and Cooper 1999), creating 306 hospital referral 
regions (HRRs) based on the migration patterns of Medicare patients to 
hospitals (Wennberg and Cooper 1999). Each HRR is required to include 
at least one major hospital performing cardiovascular surgery and neuro- 
surgery. While the larger size of the region masks the within-region (across- 
hospital) variation in hospital quality, in practice there is plenty of across- 
region variation in these measures of output quality. However, it may be 
difficult to control entirely for differences across HRRs with respect to 
underlying health status, and so unexplained variations across regions may 
be due to unmeasured confounding variables rather than quality of care 
per se. More problematic is the improved detection of enzymes that are 
markers for AMI, and thus a patient who would be designated with un- 
stable angina in one region could be labeled a non-Q-wave AM1 in another 
region. To the extent these patients are healthier than average, the mortal- 
ity estimates for that region could be biased downward. To avoid such bi- 
ases, I adopt the process-based quality measures in this paper because at 
least for the treatment of AMI, they are highly predictive of outcomes. 
8.4  The Estimated Cost of Low-Quality Care for AM1 
An  important  study  by  Heidenreich  and  McClellan  (2001) has  at- 
tempted to quantify the incremental benefits of treatments for AM1 that 
have proven effectiveness. They identify five treatments with “clear mor- 
tality  benefit”-aspirin,  beta-blockers,  thrombolytics,  ACE  inhibitors, 
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attack)-and  provide consensus marginal odds ratios (i.e., their additional 
value conditional on other treatments).6 As well, they also provide odds ra- 
tios at thirty days of the marginal effectiveness of each procedure, condi- 
tional on the value of other treatments. The approach used here is to pre- 
dict how mortality would vary across regions solely on the basis of the 
variations in the use of these effective procedures, multiplied by their effec- 
tiveness in expanding survival. 
There are two adjustments to the data before deriving predicted mortal- 
ity values in each region for the same hypothetical patient. The first is that 
the thirty-day odds ratios are assumed to be the same for one-year odds ra- 
tios. At least in the case of beta-blockers, this seems to be the case; the 
thirty-day odds ratio used in this study is 0.88, while Krumholz et al. (1998) 
estimated a one-year risk ratio between 0.77 and 0.86.7  The second adjust- 
ment is to combine angioplasty and thrombolytics as reperfusion. These 
procedures are typically substitutes (because thrombolytics increase the 
risk of bleeding during the angioplasty procedure), and just reperfusion 
rates are reported in the HRR-level data. I average their odds ratios to es- 
timate effectiveness. 
To estimate predicted mortality based solely on the HRR-level use of these 
four procedures, 1  further convert the odds ratios back into coefficients  in the 
logistics regression and then calculate the following linear index: 
4 
z*  = 8 + c  q7,> 
where y,  is the modified coefficient for thejth treatment (j  = 1, 2, 3,4), 8 
the constant term, and X,  is  the fraction of  ideal candidates receiving 
treatmentj in HRR i.  (Strictly speaking, one would like to know each in- 
dividual and their treatment vector, but that data is not available; thus I 
make a linear approximation in the context of the index.) Thus, ZL  is the lin- 
ear index of mortality in HRR i, and estimated mortality m, is exp(ZJ/[l 
+ exp(Z,)].  The constant term 8 is varied to ensure that the predicted mor- 
tality matches a 30 percent one-year mortality rate. 
Data on use of these procedures is from the Cooperative Cardiovascular 
Project that collected chart review and outcome data on more than 160,000 
heart attack patients during 1994 and 1995. The detailed information al- 
lowed researchers to define “ideal” and “appropriate” patients for each of 
the four treatments. Figure 8.1 shows the distribution of one of these treat- 
ments, beta-blocker use among ideal patients, for each of 267 HRRs. (The 
remaining HRRs were dropped because of small sample sizes.) There is a 
very large degree of variation across regions, with usage ranging from less 
than 20 percent to over 80 percent during 1994 and 1995. 
6. They are aspirin (0.77),  beta-blockers (0.88), thrombolytics (0.75),  primary angioplasty 
7. Note that odds ratios are typically larger in magnitude than risk ratios. 





Source: Dartmouth Atlas of Cardiovascular  Health Care (Wennberg and Birkmeyer 2000). 
Note: Each dot refers to an HRR. 
Percent of “ideal” patients receiving beta-blockers at discharge following 
Predicted mortality, based on the variation in the utilization of these four 
treatments, ranges from less than 28 percent (in Everett, Washington [27.4 
percent] and St. Petersburg, Florida [27.9 percent], for example) to more 
than 33 percent (Oxford, Mississippi [34.1 percent], Hattiesburg, Missis- 
sippi [33.3  percent] and Jonesboro, Arkansas [33.1 percent], for example). 
Using the adjustment from one-year mortality to expected life years used 
in Cutler et al. (1998) and placing $50,000 as the price tag for the loss of one 
life year, the average efficiency cost per AM1 patient is $3,687 compared to 
the best performing region, Everett Washington. Compared to a uniform 
compliance rate of 90 percent across all four dimensions of quality, the av- 
erage cost rises to $5,106. The extremes, of course, are much greater; for pa- 
tients living in Oxford, Mississippi who are appropriate candidates for 
these four treatments, they should be willing to pay $18,584 to be airlifted 
to Everett, Washington. 
These estimated values would be twice as high if one were to use a com- 
monly used benchmark  of $100,000 per life year and even larger under 
some recommendations (Ubel, Hirth, Chernew, and Fendrick 2003). By 
the same token, however, one can deflate the values by the percentage of 
patients deemed “ideal” for the procedures. Taking a rough estimate of 39 
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of beta-blockers) and applying this to all treatments yields a smaller mean 
cost of $1,446 (compared to Everett, Washington) and $1,758 (compared 
to a 90 percent uniform compliance rate) using the $50,000 per life year 
price tag. A compromise estimate could be using these adjusted numbers 
with a $100,000 per life year cost figure, leading to an estimate of approxi- 
mately $3,000 per person inefficient level, but with some regions showing 
benefits from better compliance as much as $10,000 per patient. In other 
words, hospitals located in the poorly performing regions during 1994 and 
1995 with 200 heart attack patients per year would have realized a social 
gain of more than $2 million annually during 1994 and 1995 had they 
simply adopted best-practice cardiac care for heart attack patients. Any 
additional costs that would have been incurred would have been either neg- 
ligible (aspirin, beta-blockers) or reimbursed by  Medicare (angioplasty). 
Given the apparently large benefits associated with the adoption of this 
technology, I next turn to considering factors affecting its adoption or non- 
adoption. 
8.5  Factors Affecting the Adoption of High-Quality Care 
First consider supply factors that might affect the adoption of new tech- 
nology. Figure 8.2 shows a graph of HRR-level beta-blocker use according 
0 
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Fig. 8.2  Per capita cardiologist population and beta-blocker use 
Source: Dartmouth Atlas of  Cardiovascular Health Care (Wennberg and Birkmeyer 2000). 
Note: Each dot represents one of the 269 HRRs with sufficient information on beta-blocker 
use (that is, percentage of patients with AM1 who are “ideal” for beta-blockers who get it). 204  Jonathan Skinner 
Table 8.1  Regression analysis explaining quality measures for cardiac care by 
HRR, 1994-1995 
Aspirin  Average 
Beta-blocker  use in the  Reperfusion  quality 
used  hospital”  used  measured 
(1)  (2)  (3)  (4) 
Cardiologist per 100,000” 
Percent college graduateh 
Poverty rateb 
Percent urbanb 
Percent cigarette smokers‘ 
AM1 rate per l,OOOd 
Constant 
Adjusted R2 
Mean of dependent variable (SD) 
0.84  -0.31 
(1.5)  (1.8) 
0.71  0.23 
(4.5)  (4.6) 
-0.82  -0.21 
-0.16  -0.04 
(5.2)  (5.0) 
(2.7)  (2.2) 
(1.4)  (2.1) 
(4.7)  (0.6) 
29.82  83.27 
(2.4)  (20.9) 
0.30  0.16 
50.89  86.12 
(13.71)  (4.29) 
-0.50  0.24 



































Notes: N = 267. Absolute value of t-statistics in parentheses. All regressions weighted by pop- 
ulation of Medicare enrollees in 1996. 
”Source: Wennberg and Birkmeyer (2000). 
bSource: 1990 Census. 
%ource: CDC Behavioral Risk Factor database. 
%ource: Wennberg and Cooper (1999). 
to the supply of cardiologists per 100,000 population. There is a modest 
positive correlation; essentially having more cardiologists helps to ensure 
that the HRR is not in the “very low” category, with rates under 40 percent. 
Table 8.1 presents least squares regression results where the dependent 
variable is the percentage of ideal patients receiving a variety of high- 
quality treatments as a function of a variety of factors, including an aver- 
age measure of quality in the rightmost column. 
The first column attempts to explain the use of beta-blocker use. The re- 
gression estimates imply that increasing the supply of cardiologists from 
the 10th percentile (4.2 per 100,000)  to the 90th percentile (9.0 per 100,000) 
is predicted to increase the use of beta-blockers by just 4 percentage points, 
and even that estimate is not significantly different from zero at the 95 per- 
cent confidence interval.* On the other hand, a greater burden of cardio- 
8. By way of comparison, the standard deviation for beta-blocker use was 14 percentage 
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Table 8.2  Beta-blocker use in Georgia 
Percent of beta-blocker use 













Source: Wennberg and Birkmeyer (2000). 
Note: Medical schools are located in Macon and Atlanta (shown in bold). 
vascular disease was associated with higher use of beta-blockers; a shift 
from the 10th to the 90th percentile in the underlying rate of AM1 per 1,000 
population of Medicare enrollees over age sixty-five was associated with a 
5.6 percentage point increase in the use of beta-blockers. As well, demand 
factors appeared to exert an influence; shifting from the 10th to the 90th 
percentile in the percentage of college graduates living in the HRR was as- 
sociated with a 5.8 percentage point higher rate of beta-blocker use. 
Nor does the supply of cardiologists appear to be correlated with rates 
of aspirin use, reperfusion, or the combined index of cardiac health care 
quality (columns [2] through [4]). As was observed in the case of  beta- 
blockers, most of the variation in the use of quality appeared associated 
with factors such as education levels and poverty rates in the region. Inter- 
estingly, the population  of  cardiologists was negatively  associated with 
reperfusion rates. While the negative association holds solely for the per 
capita population of noninterventional cardiologists (that is, those who do 
not perform angioplasty), it is still somewhat surprising that reperfusion 
should not be more closely associated even with interventional cardiolo- 
gists. This is a topic for future research. 
To this point, the presence of a medical center has not yet been included 
in the statistical analysis. However, it may be of interest to consider a state 
chosen because of the very wide range in beta-blocker compliance, ranging 
from 21 percent in Macon, Georgia to 90 percent in Albany, Georgia. At 
least in Georgia, the use of beta-blockers in a community is not positively 
associated with the presence of a medical school; table 8.2 lists each HRR 
in Georgia, with the medical schools represented in bold. Indeed, Atlanta 
and Macon show beta-blocker use well below the state average. 
8.6  Conclusion 
The starting point for this analysis was the remarkable variation in mea- 
sured quality of care for the treatment of heart attack patients across regions. 206  Jonathan Skinner 
This variation has also been observed in more recent studies across states 
(Jencks et al. 2000; Jencks, Huff, and Cuerdon 2003), with only a modest de- 
gree of convergence over time. The first question addressed in this paper is to 
quantify the extent of these inefficiencies across regions. The estimates are 
consistent with an average quality gap of between $1,800 and $5,000 per 
heart attack patient. These are estimates that are not compared to some hy- 
pothetical level of perfection, but instead relative to a region in the United 
States that has managed to make efficient use of the existing technological 
treatments for AMI. Nor do these estimates assume that delicate surgical 
skills can be effortlessly transferred across regions, as most of the gains are 
realized through pharmaceutical rather than surgical innovations. 
We also ask what factors appear to be associated with the adoption of 
effective technology. The supply of cardiologists appears to be weakly as- 
sociated with the use of beta-blockers, but not with an average of four qual- 
ity measures. Instead, quality appears to be a normal good; regions with 
higher overall income and education levels are more likely to adopt early. 
As well, regions with a higher prevalence of  cardiovascular disease are 
more likely to adopt beta-blockers and to experience higher average rates 
of effective care for AMI, suggesting that volume effects-the  ability of 
hospitals to specialize in cardiac care where there are a relatively large 
number of patients with cardiac disease-may  improve organizational en- 
vironments for adopting newer technologies. 
One unanswered question is why  the medical profession is so slow to 
adopt newer technologies, despite the clear benefits of doing so. The tradi- 
tional (noneconomic) diffusion model distinguishes between the “early 
adopters,” who are most effective at disseminating the successful ideas of 
innovators to the four-fifths of the remaining population, and the “early 
majority” and “late majority” group, who, while not entirely laggards, ac- 
count for the majority of the profession in being very slow to adopt new in- 
novations. For example, Berwick (2003) suggests that 
Medical communities are primarily local in their orientation, are domi- 
nated numerically by early and late majority groups, and do not trust re- 
mote and personally unfamiliar sources of authority. (1973) 
A topic for future research is therefore to identify whether regions that are 
more effective in adopting new technologies have a “flatter” structure of 
authority as opposed to a hierarchical one where a “late majority” depart- 
ment chair can implicitly hold up new innovations for decades. 
Regions that score well on treatment for AM1 are only modestly more 
likely to score well for other measures of process quality. The correlation 
coefficient between beta-blocker use and the provision of annual eye ex- 
aminations for diabetics in the Medicare population is 0.15 (p  <  .02), while 
the corresponding coefficient with mammography rates is 0.29 (p  < ,001). 
The low correlation across regions, as well as the low explanatory value of Geography and the Use of Effective Health Care in the United States  207 
the regressions explaining adoption, are consistent with a model where 
each physician group, whether cardiologists, cardiac surgeons, internists, 
or family practice physicians, undergo different processes regarding the 
adoption of specific technologies for their group. 
This is not to say, however, that financial incentives introduced with re- 
gard to these specific quality measures may not exert a strong and impor- 
tant impact on their overall use. One of the reasons why  the use of beta- 
blockers grew so rapidly between 1997 and 1998 and 2000 and 2001 is 
because it was one of the Health Plan Employer Data and Information Set 
(HEDIS) quality measures used to quantify health care quality at the hos- 
pital or provider level. That there is so much latitude in the potential to im- 
prove the quality of care (and at such little cost) suggests that the incentives 
of the Medicare program could be better aligned with improving quality 
rather than rewarding the quantity of services in the United States. 
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